<DOC>
<DOCNO>EP-0008003</DOCNO> 
<TEXT>
<INVENTION-TITLE>
(DL)-16-PHENOXY- AND 16-SUBSTITUTED PHENOXY-9-KETO PROSTATRIENOIC ACIDS AND DERIVATIVES AND PROCESSES FOR THE PRODUCTION THEREOF AND THEIR PHARMACEUTICAL COMPOSITIONS
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31557	C07C6700	A61P104	C07C6700	A61P100	A61K31557	C07C40100	A61K3123	A61K3121	A61P4300	C07C40500	A61P4300	C07C40100	C07C40500	A61K315575	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	C07C	A61P	C07C	A61P	A61K	C07C	A61K	A61K	A61P	C07C	A61P	C07C	C07C	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	C07C67	A61P1	C07C67	A61P1	A61K31	C07C401	A61K31	A61K31	A61P43	C07C405	A61P43	C07C401	C07C405	A61K31	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Novel 16-phenoxy and 16-(o, m or p)-substituted phen­
oxy derivatives of (dl)-9-keto-11α,15α-dihydroxy-17,18,19,20-­

tetranorprosta-4,5,13-trans-trienoic acid, the pharmaceuti­
cally acceptable, non-toxic lower alkyl esters and salts 

thereof and processes for the production of such com­
pounds. These compounds possess prostaglandin-like ac­

tivities and thus are useful in the treatment of mammals 

where prostaglandins are indicated. They are particularly 
useful as inhibitors of gastric acid secretion; and as agents 

for the control of asthmatic attack, because of their broncho-­
dilating activity. 
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
SYNTEX (U.S.A.) INC.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
DWARDS, JOHN A.
</INVENTOR-NAME>
<INVENTOR-NAME>
GARAY, GABRIEL
</INVENTOR-NAME>
<INVENTOR-NAME>
VAN HORN, ALBERT
</INVENTOR-NAME>
</INVENTORS>
</TEXT>
</DOC>
